A dipeptide formed by formal condensation of the carboxy group of (3R)-3-methyl-D-ornithine with the side-chain amino group of L-lysine.


NBD-N(Me)-DbetaA-OH

A dipeptide comprising in sequence alpha-aspartyl and beta-alanyl residues, to the nitrogen of the aspartyl residue of which are linked both a methyl group and a 7-nitro-2,1,3-benzoxadiazol-4-yl moiety.


Ile-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of L-threonine.


belongs to the class of organic compounds known as dipeptides. TMAP was previously an unknown potential plasma biomarker for glomerular filtration rate (GFR) but its structure has since been elucidated (PMID: 28706470 ). TMAP has also been identified as a potential plasma biomarker of reduced kidney function in early chronic kidney disease (CKD), end stage renal disease (ESRD), and hemodialytic clearance (PMID: 31048706 )


Thr-Gln

A dipeptide formed from L-threonine and L-glutamine residues.


L-prolylglycine

A dipeptide consisting of glycine having an L-prolyl group attached to its alpha-amino nitrogen.


Met-Thr

A dipeptide formed from L-methionine and L-threonine residues.


Phe-Ala

A dipeptide formed from L-phenylalanine and L-alanine residues.


gamma-glutamyl-Se-methylselenocysteine

A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of Se-methylselenocysteine.


Asn-Trp

A dipeptide obtained by formal condensation of the carboxy group of  L-asparagine with the amino group of L-tryptophan.


Dnp-Pro-Gln

A dipeptide consisting of L-proline substituted on nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.


Cys(IAN)-Gly

An S-conjugate in which the mercapto hydrogen of L-cysteinylglycine has been replaced by a cyano(indol-3-yl)methyl group.


alpha-Asp-Ile

A dipeptide that is the N-(L-alpha-aspartyl) derivative of L-isoleucine.


Gly-Tyr

A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage.


7-dimethylallyl neoechinulin B anion

Major microspecies at pH 7.3.


Val-Ile

A dipeptide formed from L-valine and L-isoleucine residues.


Tyr-Asn

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-asparagine.


Tyr-Gly

A dipeptide formed from L-tyrosine and glycine residues.


Tyr-Val

A dipeptide formed from L-tyrosine and L-valine residues.


Asp-Gly

A dipeptide composed of L-aspartic acid and glycine joined by a peptide linkage.


Gly-Asn

A dipeptide formed from glycine and L-asparagine residues.


glycylglycine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycylglycine with the amino group of 2-naphthylamine.


A dipeptide amide obtained by formal condensation of the carboxy group of N-benzoyl-L-valylglycine with the amino group of 4-methoxy-2-naphthylamine.


Ile-Ile

A dipeptide formed from two L-isoleucine residues.


Pro-Pro

A dipeptide formed from two L-proline residues.


Val-Asn

A dipeptide formed from L-valine and L-asparagine residues.


WLL-vs

A dipeptide that is L-tryptophyl-L-leucinamide in which the N-terminal amino group has been converted to the corresponding (morpholin-4-yl)acetamide and in which one of the hydrogens attached to the nitrogen of the C-terminal amide has been replaced by a (1E)-5-methyl-1-(methylsulfonyl)hex-1-en-3-yl group. It is a selective proteasome inhibitor.


A dipeptide comprising tyrosine with a tyrosyl residue attached to the alpha-nitrogen and with each tyrosine residue being substituted at the 3- and 5-positions by iodine.


Val-Glu

A dipeptide formed from L-valine and L-glutamic acid residues.


trandolaprilat

A heterobicyclic compound that is trandolapril in which the ethyl ester group has been hydrolysed to the corresponding acid group. It is the active metabolite of the prodrug trandolapril.


alanyl glutamine

A dipeptide formed from L-alanyl and L-glutamine residues.


Glu-Asp

A dipeptide composed of L-glutamic acid and L-aspartic acid joined by a peptide linkage.


Lys-Ser

A dipeptide formed from L-lysine and L-serine residues.


A dipeptide that is cysteinylglycine in which the thiol hydrogen has been replaced by a 4-hydroxy-1-oxononan-3-yl group.


Ser-Met

A dipeptide formed from L-serine and L-methionine residues.


Pro-Cys

A dipeptide obtained by formal condensation of the carboxy group of L-proline acid with the amino group of L-cysteine.


Asp-Glu

A dipeptide formed from L-alpha-aspartyl and L-glutamic acid residues.


Phe-Ile

A dipeptide formed from L-phenylalanine and L-isoleucine residues.


Pro-Tyr

A dipeptide formed from L-proline and L-tyrosine residues.


Asn-Leu

A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-leucine.


6-hydroxytryprostatin B

A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and hydroxy groups respectively.


OGLUFANIDE

A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage.


Ile-Arg

A dipeptide formed from L-isoleucine and L-arginine residues.


A dipeptide that is N-[(2S)-2-aminobutanoyl]glycine in which the terminal amino group has been acylated by formal condensation of the 5-carboxy group of 2-oxopentanedioic acid.


Asn-Arg

A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-arginine.


Phe-Phe

A dipeptide formed from two L-phenylalanine residues.


PROTUBONINE A

An organic heterotetracyclic compound that is 6,10b,11,11a-tetrahydro-H-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-,4(3H,5aH)-dione substituted by an acetyl group at position 6, a hydroxy group at position 10b and a 2-methylpropyl group at position 3. It has been isolated from  in Aspergillus species.


alpha-Asp-Leu

A dipeptide that is the N-(L-alpha-aspartyl) derivative of L-leucine.


name: L-Alaninamide, glycyl-N-(2-mercaptoethyl)-, 2,2'-disulfide bis(trifluoroacetate)


Asn-Asn

A dipeptide formed from two L-asparagine units.


bentiromide

The dipeptide obtained by condensation of N-benzoyl-L-tyrosine with 4-aminobenzoic acid. Used as a noninvasive screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy, it is given by mouth: the amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.


mycocyclosin

An organic heterotetracyclic compound obtained via intramolecular oxidative aromatic coupling of cyclo(L-tyrosyl-L-tyrosyl).


An N-(2-naphthyl)carboxamide obtained by formal condensation of the C-terminal carboxy group of L-glutamyl-L-glutamic acid with the amino group of 2-naphthylamine.


ombitasvir

A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.


gamma-Glu-Ala

A gamma-glutamylalanine obtained by formal condensation of the gamma-carboxy group of L-glutamic acid with the amino group of L-alanine.


Leu-Ile

A dipeptide formed from L-leucine and L-isoleucine residues.


Arg-Ala

A dipeptide formed from L-arginyl and L-alanine residues.


Gln-Val

A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of L-valine.


A dipeptide consisting of N-butyl-L-serinamide having an (R)-2-amino-2-(4-hydroxyphenyl)acetyl residue attached to its alpha-amino nitrogen. A synthetic determinant of cefadroxil, it is a promising tool for determining in vitro cross-reactivity to cefadroxil in amoxicillin-allergic patients.


Ac-D-His-Pro

A dipeptide that is the N-(N(alpha)-acetyl-D-histidyl) derivative of L-proline.


Gly-Pro

A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.


L-leucylglycine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of L-leucylglycine with the amino group of 2-naphthylamine.


Phe-Met

A dipeptide formed from L-phenylalanine and L-methionine residues.


Ser-Ile

A dipeptide obtained by formal condensation of the carboxy group of L-serine with the amino group of L-isoleucine.


Val-FMDP

A  dipeptide composed of 3-{[(2E)-4-methoxy-4-oxobut-2-enoyl]amino}alanine and L-valine joined by peptide linkages.


LEU-ALA

A dipeptide composed of L-leucine and L-alanine joined by a peptide linkage.


Pro-Asn

A dipeptide formed from L-proline and L-asparagine residues.


Cys-Cys

A dipeptide formed from two L-cysteine residues.


His-Ala

A dipeptide formed from L-histidine and L-alanine residues.


A non-proteinogenic dipeptide anion formed from L-glutamate and L-propargylglycine residues. Major species at pH 7.3.


Asn-Tyr

A dipeptide composed of L-asparagine and L-tyrosine joined by a peptide linkage.


DAPT

A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. It is a gamma-secretase inhibitor.


Tyr-Glu

A dipeptide formed from L-tyrosine and L-glutamic acid residues.


Leu-Val

A dipeptide formed L-leucine and L-valine residues.


D-Ala-Gly

A dipeptide formed from D-alanine and glycine residues.


Val-His

A dipeptide formed from L-valine and L-histidine residues.


enalaprilat

Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.


Leu-Asp

A dipeptide formed from L-leucine and L-aspartic acid residues.


gamma-Glu-Val

A glutamyl-L-amino acid that is the N-(L-gamma-glutamyl) derivative of L-leucine.


18-OXOTRYPROSTATIN A

An indole alkaloid that is tryprostatin A substituted by an oxo substituent at position 18. Isolated from Aspergillus sydowii, it exhibits cytotoxicity.


Ala-Met

A dipeptide formed from L-alanyl and L-methionine residues.


Met-Ile

A dipeptide formed from L-methionine and L-isoleucine residues.


Phe-His

A dipeptide composed of L-phenylalanine and L-histidine joined by a peptide linkage.


A substituted L-phenylalanyl-L-phenylalaninamide dipeptide. It is a potent inhibitor of protein tyrosine phosphatase.


Thr-Thr

A dipeptide composed of two L-threonine units joined by a peptide linkage.


cyclo(L-leucyl-L-leucyl)

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by isobutyl groups (the 3S,6S-diastereomer).


Lys-Val

A dipeptide formed from L-lysine and L-valine residues.


Lys-Lys

A dipeptide formed from two L-lysine residues.


gamma-Glu-Ile

A glutamyl-L-amino acid having L-isoleucine as the L-amino acid component.


DIKETOPIPERAZINE

A cyclic peptide that is piperazine in which the hydrogens at positions 2 and 5 are replaced by oxo groups.


Pro-Val

A dipeptide formed from L-proline and L-valine residues.


His-Ser

A dipeptide formed from L-histidine and L-serine residues.


Pro-Glu

A dipeptide formed from L-proline and L-glutamic acid residues.


Lys-Ile

A dipeptide formed from L-lysine and L-isoleucine residues.


N(alpha)-gamma-L-glutamylhistamine

Histamine having a gamma-L-glutamyl group attached to the side-chain nitrogen.


Asp-Ala

A dipeptide formed from L-alpha-aspartyl and L-valine residues.


Arg-Gly

A dipeptide obtained by formal condensation of the carboxy group of L-arginine with the amino group of glycine.


PHENYLALANYLTYROSINE

A dipeptide formed from L-phenylalanine and L-tyrosine residues.


Asn-Pro

A dipeptide composed of L-asparagine and L-proline joined by a peptide linkage.


Leu-D-Leu

A dipeptide formed from L-leucine and D-leucine residues.


Tyr-Met

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-methionine.


Ala-Pro

A dipeptide composed of L-alanine and L-proline joined by a peptide linkage.


Major species at pH 7.3.


cyclo(L-leucyl-L-methionyl)

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by isobutyl and 2-(methylsulfanyl)ethyl groups (the 3S,6S-diastereomer).


D-tryptophan polyoxin C

Polyoxin C in which the primary amino group has been condensed with D-tryptophan to form a peptide bond.


Asp-Gln

A dipeptide formed from L-alpha-aspartyl and L-glutamine residues.


Val-Met

A dipeptide formed from L-valine and L-methionine residues.


Thr-Arg

A dipeptide formed from L-threonine and L-arginine residues.


Phe-Gln

A dipeptide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of L-glutamine.


Tyr-Ser

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-serine.


A dipeptide obtained by formal condensation of the carboxy group of N-acetyl-L-methione with the amino group of L-asparagine.


Glu-Met

A dipeptide composed of L-glutamic acid and L-methionine joined by a peptide linkage.


Ala-Trp

A dipeptide formed from L-alanyl and L-tryptophan residues.


A dipeptide consisting of N-butyl-L-alaninamide having an (R)-2-amino-2-phenylacetyl residue attached to its alpha-amino nitrogen.


Arg-Asp

A dipeptide formed from L-arginyl and L-aspartic acid residues.


cyclo(L-Leu-L-Pro)

A homodetic cyclic peptide composed from leucyl and prolyl residues.


Tyr-His

A dipeptide formed from L-tyrosine and L-histidine residues.


Arg-Pro

A dipeptide obtained by formal condensation of the carboxy group of L-arginine with the amino group of L-proline.


Ala-Leu

A dipeptide formed from L-alanyl and L-leucine residues.


N-acetylcarnosine

A dipeptide that is the N-acetyl derivative of carnosine.


D-alanyl-D-alanine

A dipeptide comprising D-alanine with a D-alanyl residue attached to the alpha-nitrogen. It is a component of bacterial peptidoglycan and forms an important target for development of antibacterial drugs .


Arg-Leu

A dipeptide formed from L-arginyl and L-leucine residues.


Gly-D-Val

A dipeptide formed from glycine and D-valine residues.


gamma-Glu-Gly

A glutamyl-L-amino acid obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of glycine.


cyclo(L-tryptophyl-L-alanyl)

The L-tryptophan-L-alanine cyclic dipeptide is a structural moiety containing an indole diketopiperazine (DKP) scaffold


Val-Gly

A dipeptide formed from L-valine and glycine residues.


Phe-Pro

A dipeptide formed from L-phenylalanine and L-proline residues.


Trp-Ile

A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-isoleucine.


Met-Gly

A dipeptide formed from L-methionine and glycine residues.


Phe-Asp

A dipeptide formed from L-phenylalanine and L-aspartic acid residues.


His-Gly

A dipeptide formed from L-histidine and glycine residues.


Gly-D-Asp

A dipeptide formed from glycine and D-aspartic acid residues.


Trp-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-threonine.


Tyr-Trp

A dipeptide formed from L-tyrosine and L-tryptophan residues.


Met-Leu

A dipeptide formed from L-methionine and L-leucine residues.


Ile-Asp

A dipeptide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of L-aspartic acid.


Thr-Ser

A dipeptide formed from L-threonine and L-serine residues.


Ala-Gly

A dipeptide formed from L-alanyl and glycine residues.


A dipeptide resulting from the formal condensation of the carboxy group of N-benzyloxycarbonyl-L-valine with the amino group of L-phenylalanine aldehyde. It is a potent cell-permeable inhibitor of calpain I and II, and is also a gamma-secretase inhibitor.


A member of the class of 2,5-diketopiperazines that is 2,5-diketopiperazine substituted by an (aminocarbonyl)methyl group at position 3 and an isobutyl group at position 6. It is isolated from the fungus Cordyceps sinensis and exhibits significant cytotoxicity against L-929, A375 and HeLa cell lines.


Leu-Leu

A dipeptide formed from two L-leucine residues.


gamma-Glu-Tyr

A dipeptide composed of L-glutamic acid and L-tyrosine joined by a peptide linkage.


Pro-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-proline with the amino group of L-threonine.


A dipeptide consisting of a modified L-proline residue attached to glycine via a peptide linkage.


Val-Gln

A dipeptide formed from L-valine and L-glutamine residues.


Ala-Tyr

A dipeptide composed of L-alanine and L-tyrosine joined by a peptide linkage.


tyrosyltyrosine

A dipeptide comprising tyrosine with a tyrosyl residue attached to the alpha-nitrogen.


cyclo(Pro-Arg)

A homodetic cyclic peptide resulting from the formal condensation of both the amino and acid groups of proline with the acid and amino groups of arginine. It is found in the deep-sea sponge Geodia barretti.


A dipeptide that consists of two piperidine-4-carboxylic acid units (connected via amide linkages) where the amino terminus is acylated by a 3-[2-(2-{[4-(indol-3-yl)butanoyl]amino}ethoxy)ethoxy]propanoyl group and the carboxy terminus is formally condensed with the amino group of 3-[2-(2-aminoethoxy)ethoxy]propanoic acid, the carboxy group of which is in turn formally condensed with the alpha-amino group of N(6)-5-nitrofuroyllysine.


Gly-D-Ala

A dipeptide formed from glycine and D-alanine residues.


Ser-His

A dipeptide formed from L-serine and L-histidine residues.


Thr-Met

A dipeptide formed from L-threonine and L-methionine residues.


An S-conjugate in which the mercapto hydrogen of L-cysteinylglycine  has been replaced by an N-hydroxy-2-phenylethanimidoyl group.


Ser-Gly

A dipeptide formed from L-serine and glycine residues.


D-Ala-Leu

A dipeptide formed from D-alanine and L-leucine residues.


Lys-Met

A dipeptide formed from L-lysine and L-methionine residues.


beta-Asp-Arg

A dipeptide consisting of an L-aspartyl residue attached to L-arginine via the beta-carboxy group.


His-Trp

A dipeptide formed from L-histidine and L-tryptophan residues.


fluorescein-DNP hapten

An L-lysyl-L-glutamine dipetide in which the N(6) of the lysyl residue is linked to an acid-form fluorescein derivative and the glutamine residue carries an N-(2,4-dinitrophenyl)-L-alanine-containing substituent. It is used as a fluorescently labelled hapten.


L-alanyl-D-glutamic acid

A dipeptide consisting of D-glutamic acid having an L-alanyl attached to its alpha-amino group


Leu-Glu

A dipeptide formed from L-leucine and L-glutamic acid residues.


beta-citryl-Glu-Glu

A dipeptide that is Glu-Glu in which one of the amino terminal hydrogens is replaced by a beta-citryl group.


A tripeptoid arising from cleavage of both rings of a penicillin derivative.


A dipeptide in which the carboxy group of L-homocysteine forms an amide bond with the epsilon-nitrogen of N(alpha)-acetylated L-lysine


L-alanyl-L-alanine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of L-alanyl-L-alanine with the amino group of 2-naphthylamine.


Trp-Lys

A dipeptide formed from L-tryptophan and L-lysine residues.


Ser-Val

A dipeptide formed from L-serine and L-valine residues.


Phe-Arg

A dipeptide composed of L-phenylalanine and L-arginine joined by a peptide linkage.


Major species at pH 7.3.


A ceramide obtained by formal condensation of the carboxy group of henicosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.


lipid IVA

A tetra-acylated lipid A produced by E. coli as an intermediate in the lipid A biosynthetic pathway.


A resorcinol compound having a cis-heptadec-12-enyl substituent at the 5-position.


A resorcinol compound having an alkenyl substituent at the 5-position.


Stage II Low-CSD Melanoma AJCC v7

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0).  T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration.  T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration.  T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration.  T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration.  T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Ed.)


name: Stage II Cutaneous Melanoma AJCC v6 and v7

description: Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0).  T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration.  T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration.  T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration.  T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration.  T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


name: Stage II Lentigo Maligna Melanoma AJCC v6 and v7


name: Stage IIC Cutaneous Melanoma AJCC v6 and v7

description: Stage IIC includes: T4b, N0, M0.  T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


name: Stage IIB Cutaneous Melanoma AJCC v6 and v7

description: Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0).  T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration.  T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


name: Stage IIA Cutaneous Melanoma AJCC v6 and v7

description: Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration.  T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


A member of the class of aminopyrimidines that is 2,5,6-triaminopyrimidine carrying an additional hydroxy substituent at position 4.


A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer). It is a potent retinoic acid receptor gamma (RARbeta) agonist that acts as an antagonist against RARalpha and RARgamma.


An imidazolium ion resulting from the protonation  of the nitrogen at position 3 of the imidazole group of neticonazole.


A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain 42 carbons in total with 9 double bonds.


L-leucyl(1+) group

The organic cationic group formed from L-leucinium; the major structure at pH 7.3 of the L-leuyl group, formed by protonation of the alpha-amino group.


cytoglobosin F

A cytochalasan alkaloid found in Chaetomium globosum.


(2E)-2-hexenyl isovalerate

A 2-hexenyl isovalerate in which the double bond adopts a trans-configuration.


2-hexenyl isovalerate

A fatty ester resulting from the formal condensation of the carboxy group of isovaleric acid with the hydroxy group of 2-hexen-1-ol.


PENTAERYTHRITYL DINITRATE

A pentaerythritol nitrate in which two of the hydroxy groups of pentaerythritol have been converted to the corresponding nitrate ester.


isopseudostrychnine

A monoterpenoid indole alkaloid with formula C21H24N2O3, isolated from the seeds of Strychnos nux-vomica.


A butan-4-olide that is (-)-bursehernin bearing an additional hydroxy substituent at position 5 (adjacent to the two methoxy groups).


ascopyrone P

A 4-pyranone with a 2,3-double bond carrying a hydroxy group at position 3 and a hydroxymethyl group at position 6.


A member of the class pyrazines that is pyrazin-2-amine in which one of the amino protons is substituted by a ({1-[2-(1H-pyrazol-1-yl)phenyl]ethyl}amino)acetyl group.


Atypical Vascular Proliferation

description: Benign vascular proliferations following external radiation. The lesions present in adults, predominantly in elderly women following radiotherapy for breast carcinoma. They arise from the radiated skin and are papules, small vesicles, or erythematous ecchymotic plaques with prominent telangiectasias. Identical lesions can occur after radiation for cervical carcinoma, endometrial carcinoma, ovarian carcinoma, Hodgkin lymphoma, and melanoma. There is an increased risk for subsequent development of angiosarcoma.


Atypical Vascular Lesion of Breast

description: Benign vascular proliferations following external radiation for breast carcinoma. The lesions arise from the radiated skin and are papules, small vesicles, or erythematous ecchymotic plaques with prominent telangiectasias. There is an increased risk for subsequent development of angiosarcoma.


macrocyclic molecular knot

A topologically-knotted macrocycle.


name: Advanced Digestive System Neuroendocrine Tumor G3

description: Digestive system neuroendocrine tumor G3 that has spread extensively to other anatomic sites or is no longer responding to treatment.


retuline

A monoterpenoid indole alkaloid with formula C21H26N2O2, isolated from several species of Strychnos.


silicon dioxide

A silicon oxide made up of linear triatomic molecules in which a silicon atom is covalently bonded to two oxygens.


cuprous oxide nanoparticle

An inorganic nanoparticle consisting of copper(II) oxide.


nickel ferrite

A mixed metal oxide with formula Fe2NiO4.


sucroferric oxyhydroxide

An iron oxide of nanoparticulate size and poor crystallinity. It is a mineral commonly found in soil and freshwater environments and forms a core structural component in the Fe-buffering ferritin protein. It is also used in the sequestration of heavy element contaminants, and is a precursor of haematite and goethite.


nitrous oxide

A nitrogen oxide consisting of linear unsymmetrical molecules with formula N2O. While it is the most used gaseous anaesthetic in the world, its major commercial use, due to its solubility under pressure in vegetable fats combined with its non-toxicity in low concentrations, is as an aerosol spray propellant and aerating agent for canisters of 'whipped' cream.


inorganic peroxide

Compounds of structure ROOR' in which R and R' are inorganic groups.


maghemite

An iron oxide mineral with formula Fe2O3 formed by weathering of spinels containing iron(II) such as magnetite or titanomagnetite, or through dehydration and transformation of some iron oxyhydroxide minerals. A brown or yellow pigment found in various sediments and soils.


An inorganic anion resulting from the addition of an electron to nitric oxide.


diboron trioxide

A boron oxide with formula B2O3.


hematite nanoparticle

An iron oxide nanoparticle composed of hematite (Fe2O3).


chlorine perchlorate

A chlorine oxide that is the chloro derivative of perchloric acid.


ceric oxide

A metal oxide with formula CeO2. It is used for polishing glass, in coatings for infra-red filters to prevent reflection, and as an oxidant and catalyst in organic synthesis.


manganese dioxide

A manganese molecular entity with formula MnO2.


metal oxide

An inorganic oxide that is an oxide of any metal.


nickel-zinc ferrite

A mixed metal oxide with formula [Ni(1-x)Znx]Fe(III)2O4.


maghemite nanoparticle

A superparamagnetic iron oxide nanoparticle consisting of maghemite, Fe2O3.


copper oxide

Any metal oxide in which the metallic component is copper.


zinc ferrite

A mixed metal oxide with formula Fe2O4Zn.


cuprous oxide

Any copper oxide in which the metal is in the +1 oxidation state.


beryllium oxide

A beryllium molecular entity consisting of beryllium (+2 oxidation state) and oxide in the ratio 1:1. In the solid state, BeO adopts the hexagonal wurtzite structure form while in the vapour phase, it is present as discrete diatomic covalent molecules.


silicon dioxide nanoparticle

A nanoparticle consisting of silicon dioxide.


copper(II) oxide nanoparticle

An inorganic nanoparticle consisting of copper(II) oxide.


copper(II) oxide

A metal oxide that has the formula CuO. It has an ionic structure.


lead oxide

An inorganic lead salt composed from lead(2+) and oxide.


mixed metal oxide

A metal oxide that contains cations of more than one element, or cations of a single element in more than one oxidation state.


technetium dioxide

A metal oxide with formula TcO2.


name: Bladder squamous cell carcinoma recurrent

description: The reemergence of bladder squamous cell carcinoma after a period of remission.


Bladder cancer recurrent

description: The reemergence of bladder carcinoma after a period of remission.


name: Recurrent Non-Muscle Invasive Bladder Carcinoma

description: The reemergence of non-muscle invasive bladder carcinoma after a period of remission.


name: Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

description: The reemergence of non-muscle invasive bladder urothelial carcinoma after a period of remission.


name: Recurrent Muscle Invasive Bladder Urothelial Carcinoma

description: The reemergence of muscle invasive bladder urothelial carcinoma after a period of remission.


name: Recurrent Bladder Small Cell Neuroendocrine Carcinoma

description: The reemergence of bladder small cell neuroendocrine carcinoma after a period of remission.


Bladder adenocarcinoma recurrent

description: A recurrence of adenocarcinoma of the bladder after a period of remission.


Urothelial carcinoma bladder recurrent

description: The reemergence of bladder urothelial carcinoma after a period of remission.


cadmium nitrate

An inorganic nitrate salt having Cd(2+) as the counterion.


A glycopentaosylceramide having alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc as the pentasaccharide component.


A synthetic alpha-galactosylsphingamide in which the galactose ring carries a (2S,3S,4R)-3,4-dihydroxy-2-(octanoylamino)-8-oxo-8-[(8-phenyloctyl)amino]octyl moiety at O-1.


A glycosyl alditol derivative that is N-acetyl-D-galactosaminitol in which the hydroxy group at position 3 has been converted into the corresponding 2-acetamido-2-deoxy-alpha-D-galactopyranosyl derivative.


name: PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II

description: Persistent Mullerian duct syndrome due to resistance to anti-Mullerian hormone (AMH), resulting from mutations in the AMH receptor (AMHR) gene.


An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2E,23Z,26Z,29Z,32Z)-octatriacontapentaenoic acid.


name: lumenal side of smooth endoplasmic reticulum membrane

category: biolink:CellularComponent biolink:AnatomicalEntity biolink:PhysicalEssence biolink:OrganismalEntity biolink:SubjectOfInvestigation biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: The side (leaflet) of the smooth endoplasmic reticulum membrane that faces the lumen.


name: lumenal side of rough endoplasmic reticulum membrane

description: The side (leaflet) of the rough endoplasmic reticulum membrane that faces the lumen.


Stage IV Paranasal Sinus Cancer AJCC v7

description: Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)


name: Sinonasal Adenocarcinoma, Intestinal-Type with Papillary Pattern

description: An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a papillary growth pattern.


name: Stage IVA Lip and Oral Cavity Cancer AJCC v8

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a (lip): Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose).  T4a (oral cavity): Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). M0: No distant metastasis. (AJCC 8th Ed.)


name: Metastatic Salivary Gland Squamous Cell Carcinoma

description: Salivary gland squamous cell carcinoma that has spread from the original site of growth to another anatomic site.


name: Recurrent Sinonasal Squamous Cell Carcinoma

description: The reemergence of nasal cavity and paranasal sinus squamous cell carcinoma after a period of remission.


name: Adenoid cystic carcinoma of the oral cavity stage II

description: Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Locally Advanced Oral Cavity Squamous Cell Carcinoma

description: Oral cavity squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IVC Lip Cancer AJCC v6 and v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


name: Lip and Oral Cavity Cancer by AJCC v6 and v7 Stage

description: A term that refers to the staging of lip and oral cavity carcinoma according to the American Joint Committee on Cancer, 6th and 7th editions.


name: Cutaneous Squamous Cell Carcinoma of the Head and Neck by AJCC v8 Stage

description: A term that refers to the staging of cutaneous squamous cell carcinoma of the head and neck according to the American Joint Committee on Cancer, 8th edition.


Lip basal cell carcinoma

description: A basal cell carcinoma arising from the lip.


Unresectable Head and Neck Carcinoma

description: Carcinoma that arises from the head and neck region and is not amenable to surgical resection.


name: Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v7

description: Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0).  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


name: Locally Recurrent Head and Neck Squamous Cell Carcinoma

description: The reemergence of head and neck squamous cell carcinoma after a period of remission, at or adjacent to the site of the original tumor.


name: Sinonasal Spindle Cell Squamous Cell Carcinoma

description: A poorly differentiated squamous cell carcinoma arising from the sinonasal tract. It is characterized by the presence of malignant cells with spindle cell features.


name: Lower Alveolar Ridge Squamous Cell Carcinoma

description: Squamous cell carcinoma arising from the lower alveolar ridge.


name: Stage I Nasal Cavity Cancer AJCC v6 and v7

description: Stage I includes: T1, N0, M0.  T1:Tumor restricted to any one subsite, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


SMARCB1-Deficient Sinonasal Carcinoma

description: An SWI/SNF-deficient sinonasal carcinoma characterized by biallelic deletion or inactivating mutation of SMARCB1 gene. It usually affects the paranasal sinuses, especially ethmoid. It is composed of a monomorphic malignant epithelial cellular population with a predominantly basaloid or plasmacytoid/rhabdoid morphology.


name: External Auditory Canal Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the keratinizing squamous epithelium that lines the external auditory canal.


Salivary Gland Secretory Carcinoma

description: A rare, low-grade carcinoma of the salivary gland with favorable clinical outcome.  It usually arises from the parotid gland and less often from the minor salivary glands.  It shares the same histopathologic features and molecular characteristics (ETV6 gene rearrangement) with secretory breast carcinoma.


name: Sinonasal Large Cell Neuroendocrine Carcinoma

description: A large cell neuroendocrine carcinoma that arises from the nasal cavity and paranasal sinuses.


Hard Palate Adenoid Cystic Carcinoma

description: An adenoid cystic carcinoma arising from the minor salivary glands in the hard palate.


description: An adenocarcinoma that arises from the nasal cavity and paranasal sinuses. Histologically it resembles intestinal adenocarcinoma. It is associated with lengthy occupational exposure to dust.


name: Ameloblastic Carcinoma Derived From Odontogenic Cyst

description: A rare, aggressive malignant tumor that originates from an odontogenic cyst in the maxillomandibular region.  It combines the histologic features of an ameloblastoma and carcinoma.


description: Adenocarcinomas that arise from the nasal cavity and paranasal sinuses and do not resemble salivary gland adenocarcinomas. This category includes intestinal-type and non-intestinal type adenocarcinomas.


Recurrent Lip and Oral Cavity Carcinoma

description: The reemergence of lip and/or oral cavity carcinoma after a period of remission.


Metastatic Salivary Gland Carcinoma

description: A salivary gland carcinoma that has metastasized to another anatomic site.


name: Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression. T1: Tumor smaller than 2 cm in greatest dimension.  T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)


Carcinoma of base of tongue

description: A carcinoma that arises from the base of the tongue.  Representative examples include squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.


name: Stage I Sinonasal Squamous Cell Carcinoma AJCC v6 and v7

description: Stage I includes: T1, N0, M0.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0);. IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a (lip): Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose. T4a (oral cavity): Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscles of tongue, maxillary sinus, skin of face). T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in dimension. N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension. N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M1: Distant metastasis. (AJCC 6th and 7th eds.)


Head and Neck Merkel Cell Carcinoma

description: Merkel cell carcinoma that arises from the head and neck region. It usually arises from sun-exposed skin. Rare cases arising from the oral cavity and salivary glands have been reported.


name: Paranasal Sinus Neuroendocrine Carcinoma

description: A neuroendocrine carcinoma that arises from the paranasal sinuses.


name: Paranasal Sinus Small Cell Neuroendocrine Carcinoma

description: A small cell neuroendocrine carcinoma that arises from the paranasal sinuses.


name: Primary Intraosseous Squamous Cell Carcinoma Derived From Keratocystic Odontogenic Tumor

description: A rare primary intraosseous carcinoma, not otherwise specified, that arises from the lining of an odontogenic keratocyst.


name: Head and Neck Large Cell Neuroendocrine Carcinoma

description: A large cell neuroendocrine carcinoma that arises from the head and neck.


name: Upper Alveolar Ridge Squamous Cell Carcinoma

description: Squamous cell carcinoma arising from the upper alveolar ridge.


Advanced Head and Neck Carcinoma

description: A head and neck carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Posterior Tongue Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the base of the tongue.  It usually presents as a painful ulcerated lesion.


name: Sinonasal Human Papillomavirus-Related Carcinoma with Adenoid Cystic-Like Features

description: A distinctive HPV-related non-keratinizing squamous cell carcinoma of the sinonasal tract arising most frequently from the maxillary sinus or nasal cavity. Most patients present with nasal obstruction and/or epistaxis. It is characterized by the presence of basaloid cell proliferations separated by collagenous fibrous bands. The basaloid cells align around microcystic spaces.


name: Stage 0 Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

description: Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Anterior Tongue Adenoid Cystic Carcinoma

description: An adenoid cystic carcinoma arising from the minor salivary glands in the anterior tongue.


name: Unresectable Oral Cavity Squamous Cell Carcinoma

description: Oral cavity squamous cell carcinoma that is not amenable to surgical resection.


name: Squamous cell carcinoma of head and neck metastatic

description: A head and neck squamous cell carcinoma which has spread from the original site of growth to another anatomic site.


name: Stage IV Oral Cavity Mucoepidermoid Carcinoma AJCC v6 and v7

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0);. IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: (oral cavity) Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscles of tongue, maxillary sinus, skin of face).  T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in dimension.  N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.  N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M1: Distant metastasis. (AJCC 6th and 7th eds.)


Sinonasal NUT Carcinoma

description: A highly aggressive, poorly differentiated carcinoma that arises from the nasal cavity and paranasal sinuses. It is characterized by mutations and rearrangement of the NUT gene.


Sclerosing Odontogenic Carcinoma

description: A rare, low-grade primary intraosseous carcinoma of the jaws, with bland cytology, markedly sclerotic stroma, and aggressive infiltration. It is characterized by single-file thin cords, nests, and strands of epithelium in a densely sclerotic stroma. Cytologically, individual epithelial cells are bland, with infrequent mitoses. Their cytoplasm may show vacuolation or partial clearing. There is no squamous differentiation. Despite the benign appearance, there is invasion of skeletal muscle, and perineural infiltration is characteristic. (WHO 2017)


name: Sinonasal Poorly Differentiated Carcinoma

description: A poorly differentiated carcinoma that arises from the nasal cavity and/or paranasal sinuses.


name: Stage IVA Oral Cavity Cancer AJCC v6 and v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Oral cavity cancer with moderately advanced local disease.  Tumor invades adjacent structures only (e.g., through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face). T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


name: Adenoid cystic carcinoma of the oral cavity stage III

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor more than 4 cm in greatest dimension. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Salivary Gland Low Grade Adenocarcinoma, Not Otherwise Specified

description: A salivary gland adenocarcinoma, not otherwise specified, characterized by the presence of low-grade morphological features.


name: Metastatic Oral Cavity Squamous Cell Carcinoma

description: A squamous cell carcinoma of the oral cavity which has spread from the original site of growth to another anatomic site.


Sinonasal Cancer by AJCC v8 Stage

description: A term that refers to the staging of nasal cavity and paranasal sinus carcinoma according to the American Joint Committee on Cancer, 8th edition.


Metastatic Oral Cavity Carcinoma

description: A carcinoma that arises from the oral cavity and has metastasized to another anatomic site.


Ghost Cell Odontogenic Carcinoma

description: A carcinoma usually arising from the maxilla and less often the mandible.  Symptoms include swelling and paresthesia.  It is characterized by the presence of rounded islands of malignant epithelial cells in a fibrous stroma and the benign features of calcifying cystic odontogenic tumor.  The clinical course varies from slow growing and locally invasive to rapidly growing and highly aggressive with metastases.


name: Minor Salivary Gland Small Cell Neuroendocrine Carcinoma

description: An infrequent small cell carcinoma that arises from a minor salivary gland. It is characterized by the presence of neuroendocrine differentiation and a high number of mitotic figures.


Recurrent Salivary Gland Cancer

description: The reemergence of salivary gland carcinoma after a period of remission.


name: Stage IVC Nasal Cavity and Paranasal Sinus Cancer AJCC v7

description: Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)


Metastatic Lip Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the lip and has metastasized to another anatomic site.


Advanced Salivary Gland Carcinoma

description: Salivary gland carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Locally Advanced Paranasal Sinus Carcinoma

description: Paranasal sinus carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Stage IVA Oral Cavity Mucoepidermoid Carcinoma AJCC v6 and v7


name: Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

description: Cutaneous squamous cell carcinoma of the head and neck that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Stage 0 Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Locally Advanced Head and Neck Squamous Cell Carcinoma

description: A head and neck squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Paranasal Sinus Keratinizing Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the paranasal sinuses and is characterized by prominent production of keratin.


name: Platinum-Resistant Head and Neck Carcinoma

description: Head and neck carcinoma that is resistant to platinum therapy.


name: Salivary Gland Intestinal-Type Adenocarcinoma

description: An invasive adenocarcinoma that arises from the salivary gland. Morphologically, it is characterized by the presence of intestinal-type malignant epithelial cells.


name: Stage III Nasal Cavity Cancer AJCC v6 and v7

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  T1: Tumor restricted to any one subsite, with or without bony invasion.  T2: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Metastatic Lip and Oral Cavity Carcinoma

description: A carcinoma that arises from the lip and/or oral cavity and has metastasized to another anatomic site.


name: Recurrent Lip and Oral Cavity Squamous Cell Carcinoma

description: The reemergence of lip and oral cavity squamous cell carcinoma after a period of remission.


Low Grade Salivary Gland Carcinoma

description: A salivary gland carcinoma with low-grade histopathologic features.  It includes the salivary gland polymorphous low grade adenocarcinoma, salivary gland low grade cribriform cystadenocarcinoma, and low grade salivary gland mucoepidermoid carcinoma.  It usually follows a non-aggressive clinical course.


name: Stage IVB Lip and Oral Cavity Cancer AJCC v8

description: Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th Ed.)


name: Head and Neck Keratinizing Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the head and neck region and is characterized by prominent production of keratin.


Unresectable Salivary Gland Carcinoma

description: Salivary gland carcinoma that is not amenable to surgical resection.


name: Stage IVC Oral Cavity Mucoepidermoid Carcinoma AJCC v6 and v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


name: Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Oral cavity cancer with moderately advanced local disease.  Tumor invades adjacent structures only (e.g., through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face). T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7

description: Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)


Metastatic Sinonasal Carcinoma

description: Sinonasal carcinoma that has spread from its original site of growth to another anatomic site.


name: Low Grade Salivary Gland Mucoepidermoid Carcinoma

description: A salivary gland mucoepidermoid carcinoma with low-grade histopathologic features. It usually follows a non-aggressive clinical course.


Recurrent Lip Basal Cell Carcinoma

description: Reemergence of basal cell carcinoma of the lip after a period of remission.


name: Salivary Gland Polymorphous Adenocarcinoma, Cribriform Subtype

description: A salivary gland polymorphous adenocarcinoma characterized by the presence of malignant cells forming cribriform and multinodular patterns.


name: Locally Advanced Lip and Oral Cavity Carcinoma

description: Lip and oral cavity carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7

description: Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)


name: Metastatic Paranasal Sinus Squamous Cell Carcinoma

description: Paranasal sinus squamous cell carcinoma that has spread from its original site of growth to another anatomic site.


name: Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Stage II Sinonasal Squamous Cell Carcinoma AJCC v6 and v7

description: Stage II includes: T2, N0, M0.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th ed.)


name: Minor Salivary Gland Acinic Cell Carcinoma

description: An adenocarcinoma with serous acinar cell differentiation that arises from the minor salivary glands.


name: Stage II Nasal Cavity Cancer AJCC v6 and v7

description: Stage II includes: T2, N0, M0.  T2: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Head and Neck Heterotopia-Associated Carcinoma

description: A head and neck carcinoma arising from heterotopic tissue elements (i.e. histologically normal tissue of a particular type that is present at an abnormal anatomical site). (WHO 2017)


name: Stage II Oral Cavity Cancer AJCC v6 and v7

description: Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Recurrent Salivary Gland Mucoepidermoid Carcinoma

description: The reemergence of salivary gland mucoepidermoid carcinoma after a period of remission.


name: Stage 0 Lip and Oral Cavity Cancer AJCC v6 and v7

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Ameloblastic Carcinoma-Secondary Type (Dedifferentiated), Intraosseous

description: A very rare ameloblastic carcinoma that originates from a pre-existing intraosseous benign ameloblastoma.


name: Paranasal Sinus Large Cell Neuroendocrine Carcinoma

description: A large cell neuroendocrine carcinoma that arises from the paranasal sinuses.


name: SWI/SNF Complex-Deficient Sinonasal Carcinoma

description: A highly aggressive, poorly to undifferentiated carcinoma that arises from the sinonasal tract. It is characterized by loss of one SWI/SNF complex subunit (either SMARCB1 or SMARCA4) and lacks histological features to allow classification into another specific entity. Most patients present with locally advanced disease.


Head and neck cancer metastatic

description: A carcinoma that arises from the head and neck and has spread from the original site of growth to another anatomic site.


name: Locally Advanced Paranasal Sinus Squamous Cell Carcinoma

description: Paranasal sinus squamous cell carcinoma that has spread to nearby tissues or lymph nodes.


Locally Advanced Sinonasal Carcinoma

description: Sinonasal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck

description: The reemergence of cutaneous squamous cell carcinoma of the head and neck after a period of remission.


name: Stage I Lip and Oral Cavity Cancer AJCC v6 and v7

description: Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Sinonasal Adenocarcinoma

description: Adenocarcinomas that arises from the sinonasal tract. This category includes salivary-type and non-salivary type adenocarcinomas. The latter includes intestinal-type and non-intestinal-type adenocarcinomas.


name: Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Posterior Tongue Adenoid Cystic Carcinoma

description: An adenoid cystic carcinoma arising from the minor salivary glands in the base of the tongue.


name: Metastatic Salivary Gland Secretory Carcinoma

description: A salivary gland secretory carcinoma that has spread from its original site of growth to other anatomic sites.


name: Stage IVC Oral Cavity Cancer AJCC v6 and v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


adenocarcinoma of oral cavity

description: An adenocarcinoma that arises from the oral cavity.


Sinonasal Adenocarcinoma, Salivary-Type

description: Adenocarcinomas that arise from the seromucinous glands and surface epithelium of the nasal cavity and paranasal sinuses. These adenocarcinomas morphologically resemble the adenocarcinomas that arise from the major and minor salivary glands.


name: Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Oral cavity cancer with moderately advanced local disease.  Tumor invades adjacent structures only (e.g., through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face). T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


Hard Palate Mucoepidermoid Carcinoma

description: A mucoepidermoid carcinoma arising from the minor salivary glands in the hard palate.


name: Stage II Lip and Oral Cavity Cancer AJCC v8

description: Stage II includes: T2, N0, M0. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)


name: Locally Advanced Salivary Gland Carcinoma

description: A salivary gland carcinoma that has spread to nearby tissues or lymph nodes.


name: Tracheal Basaloid Squamous Cell Carcinoma

description: A high-grade, aggressive variant of squamous cell carcinoma that arises from the trachea. It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.


Adult Salivary Gland Carcinoma

description: A carcinoma of the salivary gland that occurs during adulthood.


name: Stage IV Nasal Cavity and Paranasal Sinus Cancer AJCC v6

description: Stage IV maxillary sinus cancer: Stage IV is divided into stages IVA, IVB, and IVC.  Stage IVA: cancer has spread to either one lymph node on the same side of the neck as the cancer and the lymph node is larger than 3 centimeters but smaller than 6 centimeters; or, cancer has spread to more than one lymph node anywhere in the neck, and all are 6 centimeters or smaller; cancer is also found in any of the following areas: the maxillary sinus, bones around the maxillary sinus, tissues under the skin, the eye socket, the base of the skull, and the ethmoid sinuses or cancer is found in one or more lymph nodes in the neck, none larger than 6 centimeters, and in any of the following areas: the front of the eye, the skin of the cheek, the base of the skull, behind the jaw, the bone between the eyes, and the sphenoid or frontal sinuses. Stage IVB: cancer has spread to either: one or more lymph nodes larger than 6 centimeters; or the back of the eye, the brain, the base and middle parts of the skull, nerves in the head, and/or the upper part of the throat behind the nose; cancer may also be found in one or more lymph nodes. Stage IVC: cancer has spread to other parts of the body.  Stage IV nasal cavity and ethmoid sinus cancer: Stage IV is divided into stages IVA, IVB, and IVC.  Stage IVA: cancer has spread to either one lymph node on the same side of the neck as the cancer and the lymph node is larger than 3 centimeters but smaller than 6 centimeters; or, cancer has spread to more than one lymph node anywhere in the neck, and all are 6 centimeters or smaller; cancer is also found in any of the following places: the nasal cavity or ethmoid sinus., the eye socket, the maxillary sinus, the roof of the mouth, and the bone between the eyes or cancer is found in one or more lymph nodes in the neck, and the lymph nodes are 6 centimeters or smaller; cancer is also found in any of the following areas: the front of the eye, the skin of the nose or cheek, front parts of the skull, the base of the skull, and the sphenoid or frontal sinuses.  Stage IVB: cancer is found in any of the following areas: the back of the eye, the brain, the middle parts of the skull, nerves in the head the upper part of the throat behind the nose and the base of the skull.  Cancer may also be found in one or more lymph nodes or cancer is found in a lymph node that is larger than 6 centimeters.  Stage IVC: cancer has spread to other parts of the body (from PDQ).


name: Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Lip and oral cavity cancer with moderately advanced local disease. Lip: Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose. Oral cavity: Tumor invades adjacent structures only (e.g., through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face). T1: Tumor 2 cm or less in greatest dimension. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Stage III Lip and Oral Cavity Cancer AJCC v6 and v7

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor more than 4 cm in greatest dimension. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Unresectable Sinonasal Squamous Cell Carcinoma

description: Sinonasal squamous cell carcinoma that is not amenable to surgical resection.


anaplastic carcinoma of salivary gland

description: A salivary gland carcinoma characterized by the presence of undifferentiated, anaplastic malignant epithelial cells.


Sinonasal Neuroendocrine Carcinoma

description: A neuroendocrine carcinoma that arises from the nasal cavity and paranasal sinuses.


name: Unresectable Paranasal Sinus Squamous Cell Carcinoma

description: Paranasal sinus squamous cell carcinoma that is not amenable to surgical resection.


name: Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck

description: Cutaneous squamous cell carcinoma of the head and neck that has spread from the original site of growth to another anatomic site.


Stage I Paranasal Sinus Cancer

description: Stage I includes: T1, N0, M0.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Sinonasal Cancer by AJCC v6 Stage

description: A term that refers to the staging of nasal cavity and paranasal sinus carcinoma according to the American Joint Committee on Cancer, 6th edition.


Tongue Carcinoma

description: A malignant tumor arising from the epithelium that covers the tongue.  The vast majority of tongue carcinomas are moderately or poorly differentiated squamous cell carcinomas.


name: Metastatic Oral Cavity Mucoepidermoid Carcinoma

description: A mucoepidermoid carcinoma that arises from the oral cavity and has metastasized to another anatomic site.


Carcinoma in situ of middle ear

description: An intraepithelial squamous cell carcinoma that arises from the external auditory canal without evidence of invasion.


name: Salivary Gland Poorly Differentiated Carcinoma

description: A high-grade carcinoma that arises from the salivary glands. This category includes large and small cell types with or without neuroendocrine differentiation.


name: Low Grade Papillary Schneiderian Carcinoma

description: A rare sinonasal carcinoma characterized by the presence of a papillary architecture and bland morphological features similar to the Schneiderian papilloma, a pushing pattern of stromal invasion, and an increased risk of local recurrence.


name: Adenoid cystic carcinoma of the oral cavity recurrent

description: The reemergence of adenoid cystic carcinoma in the oral cavity after a period of remission.


name: Stage IV Oral Cavity Cancer AJCC v6 and v7

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0);. IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: (oral cavity) Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscles of tongue, maxillary sinus, skin of face).  T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in dimension.  N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.  N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M1: Distant metastasis. (AJCC 6th and 7th eds.)


Recurrent Oral Cavity Carcinoma

description: The reemergence of carcinoma in the oral cavity after a period of remission.


name: Recurrent Paranasal Sinus Squamous Cell Carcinoma

description: The reemergence of paranasal sinus squamous cell carcinoma after a period of remission.


SMARCA4 -Deficient Sinonasal Carcinoma

description: An SWI/SNF-deficient sinonasal carcinoma characterized by inactivating mutation of SMARCA4 gene. It usually affects the nasal sinuses. It is composed of malignant large epithelioid anaplastic cells.


name: adenoid cystic carcinoma of floor of mouth

description: An adenoid cystic carcinoma of the oral cavity that arises from the floor of the mouth.


name: Stage I Nasal Cavity and Paranasal Sinus Cancer AJCC v8

description: Stage I includes: T1, N0, M0. T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IV Lip and Oral Cavity Cancer AJCC v6 and v7

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a (lip): Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose.  T4a (oral cavity): Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscles of tongue, maxillary sinus, skin of face).  T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in dimension.  N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.  N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M1: Distant metastasis. (AJCC 6th and 7th eds.)


Localized Head and Neck Carcinoma

description: Head and neck carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


name: Sinonasal Adenocarcinoma, Intestinal-Type with Mixed Pattern

description: An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a mixture of growth patterns.


name: Mucoepidermoid carcinoma of the oral cavity recurrent

description: The reemergence of mucoepidermoid carcinoma in the oral cavity after a period of remission.


name: Squamous cell carcinoma of the oral cavity stage IV


name: Intermediate Grade Salivary Gland Mucoepidermoid Carcinoma

description: A salivary gland mucoepidermoid carcinoma with intermediate-grade histopathologic features.


name: Cutaneous Squamous Cell Carcinoma of the Head and Neck

description: A squamous cell carcinoma that arises from the skin of the head and neck.


Stage I Lip Carcinoma

description: Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Salivary Gland Oncocytic Carcinoma

description: A high grade adenocarcinoma that arises from the salivary glands. The vast majority of cases have been described in the parotid gland.  It is characterized by the presence of malignant oncocytes.  It recurs and metastasizes to regional or distant anatomic sites.


name: Stage IVA Paranasal Sinus Cancer AJCC v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses.  Ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


Adenoid cystic carcinoma of the tongue

description: An adenoid cystic carcinoma arising from the minor salivary glands in the tongue.


name: Metastatic Salivary Gland Adenocarcinoma

description: Salivary gland adenocarcinoma that has spread from its original site of growth to another anatomic site.


Refractory Head and Neck Carcinoma

description: A head and neck carcinoma that does not respond to treatment.


Recurrent Head and Neck Carcinoma

description: The reemergence of carcinoma in the head and neck region after a period of remission.


name: Minor Salivary Gland Sclerosing Microcystic Adenocarcinoma

description: A low-grade adenocarcinoma that arises from the minor salivary glands, usually in the oral cavity. It is characterized by the presence of a biphasic population of ductal and myoepithelial cells in a collagenous stroma. The prognosis is good.


Recurrent Sinonasal Carcinoma

description: The reemergence of nasal cavity or paranasal sinus carcinoma after a period of remission.


Head and Neck NUT Carcinoma

description: A highly aggressive, poorly differentiated carcinoma that arises from the head and neck. Most cases are in the nasal cavity and paranasal sinuses. It is characterized by mutations and rearrangement of the NUT gene.


name: Minor Salivary Gland Squamous Cell Carcinoma

description: A squamous cell carcinoma that affects the minor salivary glands.


name: Stage IVA Lip and Oral Cavity Cancer AJCC v6 and v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Lip and oral cavity cancer with moderately advanced local disease.  Lip: Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose.  Oral cavity: Tumor invades adjacent structures only (e.g., through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face). T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


name: High Grade Salivary Gland Mucoepidermoid Carcinoma

description: A salivary gland mucoepidermoid carcinoma with high-grade histopathologic features. It usually follows an aggressive clinical course.


name: Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7

description: Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0).  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


Adenocarcinoma of salivary gland

description: An adenocarcinoma arising from the salivary gland.  It includes the salivary gland polymorphous low grade adenocarcinoma, salivary gland oncocytic carcinoma, salivary gland mucinous adenocarcinoma, salivary gland low grade cribriform cystadenocarcinoma, salivary gland cystadenocarcinoma, salivary gland basal cell adenocarcinoma, salivary gland acinic cell carcinoma, salivary duct carcinoma, and salivary gland adenocarcinoma not otherwise specified.


name: Recurrent Minor Salivary Gland Adenocarcinoma

description: The reemergence of minor salivary gland adenocarcinoma after a period of remission.


Stage IV Nasal Cavity Cancer

description: Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)


name: Stage IVB Paranasal Sinus Cancer AJCC v7


name: Stage II Paranasal Sinus Cancer AJCC v6 and v7

description: Stage II includes: T2, N0, M0.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v6 and v7

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Squamous cell carcinoma of the oral cavity stage II

description: Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor more than 4 cm in greatest dimension. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Sinonasal Small Cell Neuroendocrine Carcinoma

description: A very rare small cell neuroendocrine carcinoma that arises from the nose and paranasal sinuses.


name: Squamous cell carcinoma of the oral cavity stage III


name: ASPH-Positive Head and Neck Squamous Cell Carcinoma

description: A head and neck squamous cell carcinoma in which the malignant cells are positive for ASPH gene.


name: Salivary Gland Hyalinizing Clear Cell Carcinoma

description: A rare, slow-growing carcinoma that arises from the salivary glands, usually the minor salivary glands of the oral cavity. It is composed of malignant clear and eosinophilic cells in a hyalinized stroma. Most cases are associated with translocation of EWSR1 and ATF1, resulting in the formation of EWSR1-ATF1 fusion gene. The prognosis is good.


name: Salivary Gland High Grade Adenocarcinoma, Not Otherwise Specified

description: A salivary gland adenocarcinoma, not otherwise specified, characterized by the presence of high-grade morphological features.


name: Sinonasal Keratinizing Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the mucosal epithelium of the nasal cavity or the paranasal sinuses and is characterized by prominent production of keratin.


name: Stage IVC Nasal Cavity and Paranasal Sinus Cancer AJCC v8

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


name: Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8

description: Stage II includes: T2, N0, M0. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


Sinonasal Lymphoepithelial Carcinoma

description: A nonkeratinizing squamous cell carcinoma arising from the sinonasal tract. It is characterized by the presence of large cells with vesicular nuclei and prominent nucleoli, a syncytial growth pattern, and a lymphoplasmacytic infiltrate.


name: Stage I Oral Cavity Cancer AJCC v6 and v7

description: Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


name: Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

description: Stage IV includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (Any T, N3, M0); (T4, Any N, M0); (Any T, Any N, M1). T1: Tumor smaller than 2 cm in greatest dimension. T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. T3: Tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression. T4: Tumor with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion. N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Sellar Choriocarcinoma

description: A choriocarcinoma that arises from or adjacent to the sellar region.


name: Stage II Lip and Oral Cavity Cancer AJCC v6 and v7


name: Salivary Gland Microsecretory Adenocarcinoma

description: A rare, low-grade adenocarcinoma that arises from the salivary gland. Almost all cases have been described in the oral cavity. It is characterized by a microcystic growth pattern, uniform intercalated duct-like tumor cells, basophilic luminal secretions, and fibromyxoid stroma formation. It is associated with MEF2C-SS18 fusion gene expression.


Recurrent Salivary Gland Adenocarcinoma

description: The reemergence of salivary gland adenocarcinoma after a period of remission.


Locally Advanced Oral Cavity Carcinoma

description: Oral cavity carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IVA Lip Cancer AJCC v6 and v7

description: Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Lip cancer with moderately advanced local disease.  Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose.  T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


name: Minor Salivary Gland Mucoepidermoid Carcinoma

description: A carcinoma that arises from the minor salivary glands.  It usually presents as a firm and painless mass.  It is characterized by the presence of epidermoid cells, mucus producing cells, and cells of intermediate type.  The majority of cases have a favorable outcome.


description: An SWI/SNF-deficient sinonasal carcinoma characterized by inactivating mutation of SMARCB1 gene. It usually affects the nasal sinuses. It is composed of malignant epithelial cells with a predominantly oncocytoid/plasmacytoid morphology and prominent glandular formations.


name: Stage IV Lip and Oral Cavity Cancer AJCC v8

description: Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a (lip): Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose).  T4a (oral cavity): Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th Ed.)


Anterior Tongue Carcinoma

description: A carcinoma that arises from the anterior two-thirds of the tongue.  Representative examples include squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.


name: Salivary Gland Poorly Differentiated Squamous Cell Carcinoma

description: A poorly differentiated squamous cell carcinoma arising from the salivary gland.


name: Locally Advanced Sinonasal Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the nasal cavity and/or paranasal sinuses and has spread from its original site of growth to nearby tissues or lymph nodes.